Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Podium presentation showcases the clinical application of Precise™ MRD
Renowned neuroprosthetics expert joins BIOS to lead clinical strategy and advance development of the Universal Neural Interface.
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
The biomarker pTau 217 is associated with Alzheimer’s disease pathology and can be detected in plasma, providing a minimally invasive option to support other diagnostic tests.
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
Congresssional Staffer Tours
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
G2G Consulting Provides Updates from Washington D.C.
bioMérieux Recognized as Top 1% by S&P Global
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
E&I Ski Day 2025 Recap